{"product_id":"recombinant-human-il-29-protein-bhp22200036","title":"Recombinant Human IL-29 Protein","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}.bhp-desc .bhp-app-wrap{overflow-x:auto}.bhp-desc .bhp-app-table{width:100%;border-collapse:collapse;margin:12px 0 18px;font-size:14px}.bhp-desc .bhp-app-table th{background:#e8f0fb;color:#003366;text-align:left;padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-app-table td{padding:8px 10px;border:1px solid #ccd9f0;vertical-align:top}.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\u003c\/style\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eRecombinant Protein · Type III Interferon\u003c\/span\u003e\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRecombinant Human IL-29 Protein\u003c\/strong\u003e is a tag-free, non-glycosylated homodimer expressed in \u003cstrong\u003ehuman cells\u003c\/strong\u003e. It is made in an animal-free, xeno-free format and supplied lyophilized from a 0.2 µm-filtered PBS solution without carrier protein, with purity \u0026gt;95% by SDS-PAGE and endotoxin \u0026lt;0.5 EU\/µg.\u003c\/p\u003e\n\u003cp\u003eIL-29 (IFN-λ1) is a strong antiviral cytokine used to study antiviral immunity and immune regulation, including antiviral studies with hepatitis viruses such as hepatitis C virus (HCV) and hepatitis B virus (HBV), immune modulation and antitumor activity research. The manufacturer expresses this human protein in human cells, with extremely low endotoxin and high purity.\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eExpression system: Human cells · Tag-free · Animal-free\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eIL-29 belongs to the type III interferon family, which is distinct from the type I IFNs. Its expression is induced by viral infection or double-stranded RNA.\u003c\/p\u003e\n\u003cp\u003eIL-29 is a ligand for the heterodimeric class II cytokine receptor formed by IL10RB and IFNLR1. Receptor engagement activates JAK\/STAT signaling and the expression of IFN-stimulated genes (ISGs), which establish the antiviral state. IL-29 has antiviral, antitumour and immunomodulatory activities.\u003c\/p\u003e\n\u003cp\u003eIL-29 acts mainly on epithelial cells, because its receptor subunit IFNLR1 is expressed specifically on that cell type. It also has an immunomodulatory effect through up-regulation of MHC class I antigen expression.\u003c\/p\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cp\u003eIL-29 is used mainly in antiviral-immunity and immune-regulation research; the main research areas are listed below.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAntiviral activity: inhibition of virus replication in studies with hepatitis C virus (HCV) and hepatitis B virus (HBV).\u003c\/li\u003e\n\u003cli\u003eImmunomodulation: modulation of the immune response, with possible relevance to autoimmune disease.\u003c\/li\u003e\n\u003cli\u003eAntitumor activity research: antitumor effects of type III interferons.\u003c\/li\u003e\n\u003cli\u003eBasic research: antiviral immunity and immune regulation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eProtein Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eIL-29\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAlternative names\u003c\/th\u003e\n\u003ctd\u003eIFN-λ1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecies\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eExpression system\u003c\/th\u003e\n\u003ctd\u003eHuman cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStructure\u003c\/th\u003e\n\u003ctd\u003eNon-glycosylated homodimer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eProtein family\u003c\/th\u003e\n\u003ctd\u003eType III interferon family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003ctd\u003eTag-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAnimal origin\u003c\/th\u003e\n\u003ctd\u003eAnimal-free \/ xeno-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular weight\u003c\/th\u003e\n\u003ctd\u003e29–35 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity\u003c\/th\u003e\n\u003ctd\u003e\u0026gt;95% by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eEndotoxin level\u003c\/th\u003e\n\u003ctd\u003e\u0026lt;0.5 EU\/µg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eLyophilized from a 0.2 µm-filtered solution in PBS without carrier protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLyophilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiological activity\u003c\/th\u003e\n\u003ctd\u003eAntiviral activity in A549 cells (human lung adenocarcinoma epithelial cell line) infected with encephalomyocarditis (EMC) virus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eApplications\u003c\/th\u003e\n\u003ctd\u003eStem Cell Differentiation, Immunotherapy, Virus studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eBiological Activity \u0026amp; Quality Control\u003c\/h2\u003e\n\u003cp\u003eBiological activity is measured by the antiviral effect of the protein in A549 cells (a human lung adenocarcinoma epithelial cell line) infected with encephalomyocarditis (EMC) virus.\u003c\/p\u003e\n\u003cp\u003eLot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.\u003c\/p\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eBriefly centrifuge the vial before opening.\u003c\/li\u003e\n\u003cli\u003eReconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.\u003c\/li\u003e\n\u003cli\u003eStore the reconstituted protein under sterile conditions at 2°C to 8°C for up to 1 month, or at −20°C to −80°C for up to 3 months.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles; a manual-defrost freezer is recommended.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eStorage \u0026amp; Shipping\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eAs supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003ePlease contact us to confirm shipping conditions for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eSelected References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eSheppard P, Kindsvogel W, Xu W, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4:63-68. \u003ca href=\"https:\/\/doi.org\/10.1038\/ni873\" target=\"_blank\" rel=\"noopener\"\u003e10.1038\/ni873\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eDonnelly RP, Kotenko SV (2010) Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30:555-564. \u003ca href=\"https:\/\/doi.org\/10.1089\/jir.2010.0078\" target=\"_blank\" rel=\"noopener\"\u003e10.1089\/jir.2010.0078\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eKotenko SV, Gallagher G, Baurin VV, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69-77. \u003ca href=\"https:\/\/doi.org\/10.1038\/ni875\" target=\"_blank\" rel=\"noopener\"\u003e10.1038\/ni875\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\u003cp style=\"margin:0\"\u003eHandle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.\u003c\/p\u003e\u003c\/div\u003e\n\u003cp\u003e\u003cem\u003eFor research use only. Not for diagnostic or therapeutic use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"StemImmune LLC","offers":[{"title":"10 ug","offer_id":67641425035629,"sku":"HIN-I29-0010","price":109.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":67641437618541,"sku":"HIN-I29-0100","price":866.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/IL29-500x500.png?v=1791572887","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-il-29-protein-bhp22200036","provider":"BioHippo","version":"1.0","type":"link"}